25 XP   0   0   10

Orient Europharma Co Ltd
Buy, Hold or Sell?

Let's analyse Orient Europharma Co Ltd together

PenkeI guess you are interested in Orient Europharma Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Orient Europharma Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Orient Europharma Co Ltd

I send you an email if I find something interesting about Orient Europharma Co Ltd.

Quick analysis of Orient Europharma Co Ltd (30 sec.)










What can you expect buying and holding a share of Orient Europharma Co Ltd? (30 sec.)

How much money do you get?

How much money do you get?
NT$0.00
When do you have the money?
1 year
How often do you get paid?
85.7%

What is your share worth?

Current worth
NT$47.98
Expected worth in 1 year
NT$56.27
How sure are you?
66.7%

+ What do you gain per year?

Total Gains per Share
NT$8.36
Return On Investment
20.4%

For what price can you sell your share?

Current Price per Share
NT$41.05
Expected price per share
NT$37.70 - NT$47.60
How sure are you?
50%

1. Valuation of Orient Europharma Co Ltd (5 min.)




Live pricePrice per Share (EOD)

NT$41.05

Intrinsic Value Per Share

NT$22.30 - NT$30.81

Total Value Per Share

NT$70.29 - NT$78.80

2. Growth of Orient Europharma Co Ltd (5 min.)




Is Orient Europharma Co Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$127.7m$106.7m$15.2m12.5%

How much money is Orient Europharma Co Ltd making?

Current yearPrevious yearGrowGrow %
Making money$1.1m-$2.3m$3.4m315.9%
Net Profit Margin2.6%-6.7%--

How much money comes from the company's main activities?

3. Financial Health of Orient Europharma Co Ltd (5 min.)




What can you expect buying and holding a share of Orient Europharma Co Ltd? (5 min.)

Welcome investor! Orient Europharma Co Ltd's management wants to use your money to grow the business. In return you get a share of Orient Europharma Co Ltd.

What can you expect buying and holding a share of Orient Europharma Co Ltd?

First you should know what it really means to hold a share of Orient Europharma Co Ltd. And how you can make/lose money.

Speculation

The Price per Share of Orient Europharma Co Ltd is NT$41.05. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Orient Europharma Co Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Orient Europharma Co Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is NT$47.98. Based on the TTM, the Book Value Change Per Share is NT$2.07 per quarter. Based on the YOY, the Book Value Change Per Share is NT$-0.03 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is NT$0.02 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Orient Europharma Co Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 NT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per Share
Usd Eps0.120.3%-0.010.0%-0.03-0.1%0.000.0%0.000.0%
Usd Book Value Change Per Share0.000.0%0.060.2%0.000.0%0.000.0%0.070.2%
Usd Dividend Per Share0.000.0%0.000.0%0.020.1%0.030.1%0.030.1%
Usd Total Gains Per Share0.000.0%0.060.2%0.020.0%0.030.1%0.100.3%
Usd Price Per Share1.19-1.26-1.11-1.38-1.39-
Price to Earnings Ratio2.48--8.39-1.57-0.09-2.95-
Price-to-Total Gains Ratio-2,573.96--630.93-29.73--147.72--140.63-
Price to Book Ratio0.81-0.89-0.91-1.03-1.03-
Price-to-Total Gains Ratio-2,573.96--630.93-29.73--147.72--140.63-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.260235
Number of shares793
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.03
Usd Book Value Change Per Share0.060.00
Usd Total Gains Per Share0.060.03
Gains per Quarter (793 shares)50.9025.34
Gains per Year (793 shares)203.62101.36
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
12202194100191
244033982002192
366056023013293
488078064015394
510100910105016495
611121012146017596
713141214187028697
815161416228029798
9171815182690210899
1019201720301002111000

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%4.08.00.033.3%10.010.00.050.0%11.010.00.052.4%11.010.00.052.4%
Book Value Change Per Share3.01.00.075.0%6.06.00.050.0%10.010.00.050.0%11.010.00.052.4%11.010.00.052.4%
Dividend per Share1.00.03.025.0%9.00.03.075.0%17.00.03.085.0%18.00.03.085.7%18.00.03.085.7%
Total Gains per Share3.01.00.075.0%8.04.00.066.7%13.07.00.065.0%14.07.00.066.7%14.07.00.066.7%

Fundamentals of Orient Europharma Co Ltd

About Orient Europharma Co Ltd

Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include cardiovascular, metabolism, neurology, obstetrics and gynecology, respiratory, andrology, immunology, antibiotic, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk and nutritional supplements under the Karihome, Babecare, and Ostricare brands; and healthcare supplements, such as thermal water for the treatment of oral and periodontal diseases under the Buccotherm name. In addition, the company offers essences, creams, lotions, eye creams, facial treatment toners, and skin repairing essences under the AGLab name; skincare oils, body lotions, and dry skin gels under the Bio-Oil name; and children skincare products under the Mister Baby brand, as well as operates ISISPHARMA, a dermatology laboratory specialized in the development and distribution of dermo-cosmetic products. Further, it engages in the research and development of Multikine, an immunotherapy drug for head and neck cancer, which is in Phase III clinical study; NC-6004, a platinum-based micelle chemotherapeutic drug that is in Phase III clinical study; ASC-J9, a molecular chemical entity drug that has completed Phase IIb clinical study for androgen receptor degradation; and 2ccPA, a derivative of phospholipid to patients with symptomatic osteoarthritis of the knee, which is in Phase I clinical trail. Orient EuroPharma Co., Ltd. was founded in 1982 and is based in Taipei, Taiwan.

Fundamental data was last updated by Penke on 2024-04-16 21:55:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just not able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Orient Europharma Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Orient Europharma Co Ltd earns for each NT$1 of revenue.

  • Above 10% is considered healthy but always compare Orient Europharma Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 28.0% means that NT$0.28 for each NT$1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Orient Europharma Co Ltd:

  • The MRQ is 28.0%. The company is making a huge profit. +2
  • The TTM is 2.6%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ28.0%TTM2.6%+25.4%
TTM2.6%YOY-6.7%+9.4%
TTM2.6%5Y1.1%+1.5%
5Y1.1%10Y1.1%0.0%
1.1.2. Return on Assets

Shows how efficient Orient Europharma Co Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Orient Europharma Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 3.1% Return on Assets means that Orient Europharma Co Ltd generated NT$0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Orient Europharma Co Ltd:

  • The MRQ is 3.1%. Using its assets, the company is less efficient in making profit.
  • The TTM is 0.3%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ3.1%TTM0.3%+2.8%
TTM0.3%YOY-0.8%+1.1%
TTM0.3%5Y0.3%+0.1%
5Y0.3%10Y0.3%+0.0%
1.1.3. Return on Equity

Shows how efficient Orient Europharma Co Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Orient Europharma Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 9.7% Return on Equity means Orient Europharma Co Ltd generated NT$0.10 for each NT$1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Orient Europharma Co Ltd:

  • The MRQ is 9.7%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 0.9%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ9.7%TTM0.9%+8.7%
TTM0.9%YOY-2.7%+3.6%
TTM0.9%5Y0.5%+0.4%
5Y0.5%10Y0.5%0.0%

1.2. Operating Efficiency of Orient Europharma Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Orient Europharma Co Ltd is operating .

  • Measures how much profit Orient Europharma Co Ltd makes for each NT$1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Orient Europharma Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated NT$0.00  for each NT$1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Orient Europharma Co Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-2.1%+2.1%
TTM-2.1%YOY-3.1%+0.9%
TTM-2.1%5Y0.7%-2.8%
5Y0.7%10Y0.6%+0.1%
1.2.2. Operating Ratio

Measures how efficient Orient Europharma Co Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.39 means that the operating costs are NT$1.39 for each NT$1 in net sales.

Let's take a look of the Operating Ratio trends of Orient Europharma Co Ltd:

  • The MRQ is 1.392. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.519. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.392TTM1.519-0.127
TTM1.519YOY1.600-0.082
TTM1.5195Y1.542-0.024
5Y1.54210Y1.543-0.001

1.3. Liquidity of Orient Europharma Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Orient Europharma Co Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.14 means the company has NT$1.14 in assets for each NT$1 in short-term debts.

Let's take a look of the Current Ratio trends of Orient Europharma Co Ltd:

  • The MRQ is 1.139. The company is just able to pay all its short-term debts.
  • The TTM is 1.096. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.139TTM1.096+0.043
TTM1.096YOY1.173-0.077
TTM1.0965Y1.497-0.402
5Y1.49710Y1.536-0.039
1.3.2. Quick Ratio

Measures if Orient Europharma Co Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Orient Europharma Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.29 means the company can pay off NT$0.29 for each NT$1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Orient Europharma Co Ltd:

  • The MRQ is 0.288. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.242. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.288TTM0.242+0.046
TTM0.242YOY0.216+0.026
TTM0.2425Y0.287-0.044
5Y0.28710Y0.300-0.013

1.4. Solvency of Orient Europharma Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Orient Europharma Co Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Orient Europharma Co Ltd to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.62 means that Orient Europharma Co Ltd assets are financed with 61.5% credit (debt) and the remaining percentage (100% - 61.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Orient Europharma Co Ltd:

  • The MRQ is 0.615. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.637. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.615TTM0.637-0.022
TTM0.637YOY0.654-0.017
TTM0.6375Y0.574+0.063
5Y0.57410Y0.567+0.007
1.4.2. Debt to Equity Ratio

Measures if Orient Europharma Co Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Orient Europharma Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 189.2% means that company has NT$1.89 debt for each NT$1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Orient Europharma Co Ltd:

  • The MRQ is 1.892. The company is just able to pay all its debts with equity.
  • The TTM is 2.100. The company is just not able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.892TTM2.100-0.208
TTM2.100YOY2.228-0.128
TTM2.1005Y1.685+0.415
5Y1.68510Y1.650+0.035

2. Market Valuation of Orient Europharma Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every NT$1 in earnings Orient Europharma Co Ltd generates.

  • Above 15 is considered overpriced but always compare Orient Europharma Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 2.48 means the investor is paying NT$2.48 for every NT$1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Orient Europharma Co Ltd:

  • The EOD is 2.619. Based on the earnings, the company is cheap. +2
  • The MRQ is 2.482. Based on the earnings, the company is cheap. +2
  • The TTM is -8.393. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD2.619MRQ2.482+0.137
MRQ2.482TTM-8.393+10.875
TTM-8.393YOY1.574-9.967
TTM-8.3935Y0.093-8.486
5Y0.09310Y2.945-2.852
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Orient Europharma Co Ltd:

  • The EOD is 3.106. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 2.943. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 1.033. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD3.106MRQ2.943+0.163
MRQ2.943TTM1.033+1.910
TTM1.033YOY-12.652+13.685
TTM1.0335Y-1.041+2.074
5Y-1.04110Y-1.237+0.196
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Orient Europharma Co Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 0.81 means the investor is paying NT$0.81 for each NT$1 in book value.

Let's take a look of the Price to Book Ratio trends of Orient Europharma Co Ltd:

  • The EOD is 0.855. Based on the equity, the company is cheap. +2
  • The MRQ is 0.811. Based on the equity, the company is cheap. +2
  • The TTM is 0.895. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.855MRQ0.811+0.045
MRQ0.811TTM0.895-0.084
TTM0.895YOY0.906-0.011
TTM0.8955Y1.025-0.130
5Y1.02510Y1.028-0.003
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Orient Europharma Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.0942.071-105%-0.027-71%0.012-906%2.285-104%
Book Value Per Share--47.98445.808+5%40.071+20%43.610+10%43.808+10%
Current Ratio--1.1391.096+4%1.173-3%1.497-24%1.536-26%
Debt To Asset Ratio--0.6150.637-3%0.654-6%0.574+7%0.567+8%
Debt To Equity Ratio--1.8922.100-10%2.228-15%1.685+12%1.650+15%
Dividend Per Share--0.0790.020+300%0.676-88%1.029-92%1.066-93%
Eps--3.919-0.210+105%-0.896+123%0.106+3606%0.111+3429%
Free Cash Flow Per Share--3.3040.058+5553%-2.478+175%-1.100+133%-1.167+135%
Free Cash Flow To Equity Per Share--3.3040.381+767%-1.244+138%0.160+1962%0.154+2043%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--30.813--------
Intrinsic Value_10Y_min--22.304--------
Intrinsic Value_1Y_max---7.220--------
Intrinsic Value_1Y_min---7.097--------
Intrinsic Value_3Y_max---13.837--------
Intrinsic Value_3Y_min---13.368--------
Intrinsic Value_5Y_max---10.983--------
Intrinsic Value_5Y_min---10.871--------
Market Cap3560968619.200+5%3374462345.6003550125231.200-5%3147835536.400+7%3888655804.560-13%3918697152.838-14%
Net Profit Margin--0.2800.026+960%-0.067+124%0.011+2407%0.011+2387%
Operating Margin----0.0210%-0.0310%0.007-100%0.006-100%
Operating Ratio--1.3921.519-8%1.600-13%1.542-10%1.543-10%
Pb Ratio0.855+5%0.8110.895-9%0.906-10%1.025-21%1.028-21%
Pe Ratio2.619+5%2.482-8.393+438%1.574+58%0.093+2565%2.945-16%
Price Per Share41.050+5%38.90040.925-5%36.288+7%44.828-13%45.174-14%
Price To Free Cash Flow Ratio3.106+5%2.9431.033+185%-12.652+530%-1.041+135%-1.237+142%
Price To Total Gains Ratio-2716.223-6%-2573.961-630.930-75%29.734-8757%-147.718-94%-140.634-95%
Quick Ratio--0.2880.242+19%0.216+33%0.287+0%0.300-4%
Return On Assets--0.0310.003+815%-0.008+125%0.003+1096%0.003+1097%
Return On Equity--0.0970.009+937%-0.027+128%0.005+1757%0.005+1748%
Total Gains Per Share---0.0152.091-101%0.649-102%1.041-101%3.351-100%
Usd Book Value--127788136.000121993710.550+5%106713660.500+20%116140493.065+10%116665616.638+10%
Usd Book Value Change Per Share---0.0030.064-105%-0.001-71%0.000-906%0.070-104%
Usd Book Value Per Share--1.4731.406+5%1.230+20%1.339+10%1.345+10%
Usd Dividend Per Share--0.0020.001+300%0.021-88%0.032-92%0.033-93%
Usd Eps--0.120-0.006+105%-0.027+123%0.003+3606%0.003+3429%
Usd Free Cash Flow--8800155.000155672.025+5553%-6599287.350+175%-2928262.705+133%-3108578.205+135%
Usd Free Cash Flow Per Share--0.1010.002+5553%-0.076+175%-0.034+133%-0.036+135%
Usd Free Cash Flow To Equity Per Share--0.1010.012+767%-0.038+138%0.005+1962%0.005+2043%
Usd Market Cap109321736.609+5%103595994.010108988844.598-5%96638550.967+7%119381733.200-13%120304002.592-14%
Usd Price Per Share1.260+5%1.1941.256-5%1.114+7%1.376-13%1.387-14%
Usd Profit--10436096.6001104762.525+845%-2385413.025+123%614429.800+1599%612707.676+1603%
Usd Revenue--37246867.10035242786.450+6%36306242.125+3%39244250.545-5%39476486.762-6%
Usd Total Gains Per Share--0.0000.064-101%0.020-102%0.032-101%0.103-100%
 EOD+3 -5MRQTTM+24 -10YOY+23 -115Y+18 -1710Y+18 -17

3.2. Fundamental Score

Let's check the fundamental score of Orient Europharma Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-152.619
Price to Book Ratio (EOD)Between0-10.855
Net Profit Margin (MRQ)Greater than00.280
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.288
Current Ratio (MRQ)Greater than11.139
Debt to Asset Ratio (MRQ)Less than10.615
Debt to Equity Ratio (MRQ)Less than11.892
Return on Equity (MRQ)Greater than0.150.097
Return on Assets (MRQ)Greater than0.050.031
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Orient Europharma Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.594
Ma 20Greater thanMa 5042.730
Ma 50Greater thanMa 10041.578
Ma 100Greater thanMa 20040.150
OpenGreater thanClose40.600
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in TWD. All numbers in thousands.

Summary
Total Assets10,811,794
Total Liabilities6,649,314
Total Stockholder Equity3,514,485
 As reported
Total Liabilities 6,649,314
Total Stockholder Equity+ 3,514,485
Total Assets = 10,811,794

Assets

Total Assets10,811,794
Total Current Assets4,227,641
Long-term Assets6,584,153
Total Current Assets
Cash And Cash Equivalents 1,736,116
Short-term Investments 405,207
Net Receivables 664,343
Inventory 1,095,799
Other Current Assets 62,348
Total Current Assets  (as reported)4,227,641
Total Current Assets  (calculated)3,963,813
+/- 263,828
Long-term Assets
Property Plant Equipment 4,018,923
Long-term Assets Other 47,901
Long-term Assets  (as reported)6,584,153
Long-term Assets  (calculated)4,066,824
+/- 2,517,329

Liabilities & Shareholders' Equity

Total Current Liabilities3,712,225
Long-term Liabilities2,937,089
Total Stockholder Equity3,514,485
Total Current Liabilities
Short Long Term Debt 2,597,524
Accounts payable 346,865
Total Current Liabilities  (as reported)3,712,225
Total Current Liabilities  (calculated)2,944,389
+/- 767,836
Long-term Liabilities
Long term Debt 1,790,083
Capital Lease Obligations Min Short Term Debt454,845
Long-term Liabilities Other 23,437
Long-term Liabilities  (as reported)2,937,089
Long-term Liabilities  (calculated)2,268,365
+/- 668,724
Total Stockholder Equity
Retained Earnings 1,305,381
Total Stockholder Equity (as reported)3,514,485
Total Stockholder Equity (calculated)1,305,381
+/- 2,209,104
Other
Capital Stock867,471
Common Stock Shares Outstanding 86,747
Net Debt 2,651,491
Net Invested Capital 7,902,092
Net Working Capital 515,416
Property Plant and Equipment Gross 4,018,923



Balance Sheet

Currency in TWD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
> Total Assets 
7,239,678
7,413,209
7,567,528
7,755,397
7,872,729
7,984,282
8,139,966
8,041,684
8,159,639
8,157,315
8,280,377
8,572,816
9,403,438
9,998,802
9,811,867
10,014,276
10,430,304
10,690,124
10,972,949
11,314,613
10,811,794
10,811,79411,314,61310,972,94910,690,12410,430,30410,014,2769,811,8679,998,8029,403,4388,572,8168,280,3778,157,3158,159,6398,041,6848,139,9667,984,2827,872,7297,755,3977,567,5287,413,2097,239,678
   > Total Current Assets 
3,962,461
3,794,813
3,884,054
4,047,521
4,185,268
4,211,135
4,273,150
4,257,910
4,317,062
4,253,888
4,005,080
3,984,923
3,925,196
4,124,853
4,009,502
3,995,813
4,185,056
4,231,989
4,118,420
4,414,925
4,227,641
4,227,6414,414,9254,118,4204,231,9894,185,0563,995,8134,009,5024,124,8533,925,1963,984,9234,005,0804,253,8884,317,0624,257,9104,273,1504,211,1354,185,2684,047,5213,884,0543,794,8133,962,461
       Cash And Cash Equivalents 
1,750,882
1,586,269
1,644,766
1,684,647
1,752,171
1,985,923
2,137,621
2,000,009
2,121,392
2,011,290
1,857,444
1,854,422
1,959,301
2,212,057
2,107,269
2,090,290
1,801,021
1,847,721
1,744,662
1,855,836
1,736,116
1,736,1161,855,8361,744,6621,847,7211,801,0212,090,2902,107,2692,212,0571,959,3011,854,4221,857,4442,011,2902,121,3922,000,0092,137,6211,985,9231,752,1711,684,6471,644,7661,586,2691,750,882
       Short-term Investments 
171,800
121,800
121,800
91,800
81,800
61,800
81,800
207,766
207,638
202,762
189,525
154,438
95,930
88,668
89,193
89,309
151,151
230,123
272,675
201,351
405,207
405,207201,351272,675230,123151,15189,30989,19388,66895,930154,438189,525202,762207,638207,76681,80061,80081,80091,800121,800121,800171,800
       Net Receivables 
785,489
670,114
589,400
680,424
723,962
732,984
608,374
527,599
542,229
595,568
596,910
657,055
613,553
621,497
604,997
619,285
758,146
622,118
727,140
628,902
664,343
664,343628,902727,140622,118758,146619,285604,997621,497613,553657,055596,910595,568542,229527,599608,374732,984723,962680,424589,400670,114785,489
       Inventory 
1,104,053
1,095,276
1,176,385
1,281,201
1,478,101
1,278,115
1,300,717
1,380,691
1,349,799
1,348,529
1,227,523
1,162,621
1,081,846
1,006,933
1,038,179
1,027,808
1,304,251
1,233,070
1,238,617
1,196,084
1,095,799
1,095,7991,196,0841,238,6171,233,0701,304,2511,027,8081,038,1791,006,9331,081,8461,162,6211,227,5231,348,5291,349,7991,380,6911,300,7171,278,1151,478,1011,281,2011,176,3851,095,2761,104,053
       Other Current Assets 
19,242
34,696
31,620
33,330
6,242
11,226
11,966
11,851
8,048
9,574
12,276
20,506
53,626
47,351
23,750
27,126
88,624
51,614
55,748
50,337
62,348
62,34850,33755,74851,61488,62427,12623,75047,35153,62620,50612,2769,5748,04811,85111,96611,2266,24233,33031,62034,69619,242
   > Long-term Assets 
0
3,618,396
3,683,474
3,707,876
3,687,461
3,773,147
3,866,816
3,783,774
3,842,577
3,903,427
4,275,297
4,587,893
5,478,242
5,873,949
5,802,365
6,018,463
6,245,248
6,458,135
6,854,529
6,899,688
6,584,153
6,584,1536,899,6886,854,5296,458,1356,245,2486,018,4635,802,3655,873,9495,478,2424,587,8934,275,2973,903,4273,842,5773,783,7743,866,8163,773,1473,687,4613,707,8763,683,4743,618,3960
       Property Plant Equipment 
2,444,358
2,715,768
2,691,831
2,828,050
2,827,220
2,937,128
2,931,845
2,895,869
2,894,013
2,871,807
3,209,896
3,342,862
4,180,566
4,653,391
4,621,924
4,933,636
4,105,681
4,068,581
4,086,482
4,053,503
4,018,923
4,018,9234,053,5034,086,4824,068,5814,105,6814,933,6364,621,9244,653,3914,180,5663,342,8623,209,8962,871,8072,894,0132,895,8692,931,8452,937,1282,827,2202,828,0502,691,8312,715,7682,444,358
       Long Term Investments 
107,303
124,684
164,555
157,519
145,699
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000145,699157,519164,555124,684107,303
       Intangible Assets 
86,351
87,587
98,630
119,794
123,981
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000123,981119,79498,63087,58786,351
       Long-term Assets Other 
0
33,954
38,772
39,856
65,772
61,506
59,636
60,687
62,546
60,766
38,119
50,412
49,876
46,269
38,404
38,645
37,392
38,683
37,177
43,552
47,901
47,90143,55237,17738,68337,39238,64538,40446,26949,87650,41238,11960,76662,54660,68759,63661,50665,77239,85638,77233,9540
> Total Liabilities 
3,097,395
3,139,311
3,651,984
3,840,310
4,060,987
4,066,322
4,206,421
3,998,992
4,254,598
4,271,573
4,780,184
5,264,789
5,950,356
6,428,997
6,348,558
6,587,104
6,986,530
6,983,804
7,117,421
7,143,995
6,649,314
6,649,3147,143,9957,117,4216,983,8046,986,5306,587,1046,348,5586,428,9975,950,3565,264,7894,780,1844,271,5734,254,5983,998,9924,206,4214,066,3224,060,9873,840,3103,651,9843,139,3113,097,395
   > Total Current Liabilities 
1,711,954
1,492,939
2,017,284
2,213,981
2,415,847
2,320,218
2,413,545
2,193,138
2,428,872
2,484,997
2,925,425
3,209,539
3,231,910
3,327,358
3,347,495
3,473,892
3,793,271
3,750,430
4,010,958
4,057,907
3,712,225
3,712,2254,057,9074,010,9583,750,4303,793,2713,473,8923,347,4953,327,3583,231,9103,209,5392,925,4252,484,9972,428,8722,193,1382,413,5452,320,2182,415,8472,213,9812,017,2841,492,9391,711,954
       Short-term Debt 
57,472
645,097
810,316
1,009,252
1,290,931
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000001,290,9311,009,252810,316645,09757,472
       Short Long Term Debt 
57,472
645,097
810,316
1,009,252
1,290,931
1,392,376
1,216,621
1,153,011
1,228,876
1,478,183
1,901,080
2,074,315
2,054,022
2,092,202
2,236,290
2,556,798
2,544,765
2,598,084
2,753,401
2,889,473
2,597,524
2,597,5242,889,4732,753,4012,598,0842,544,7652,556,7982,236,2902,092,2022,054,0222,074,3151,901,0801,478,1831,228,8761,153,0111,216,6211,392,3761,290,9311,009,252810,316645,09757,472
       Accounts payable 
318,111
267,066
392,410
351,134
334,402
280,761
256,790
296,757
318,762
276,458
169,446
158,542
159,813
211,595
160,483
198,389
552,199
507,879
532,391
421,258
346,865
346,865421,258532,391507,879552,199198,389160,483211,595159,813158,542169,446276,458318,762296,757256,790280,761334,402351,134392,410267,066318,111
       Other Current Liabilities 
275,821
80,346
83,178
88,721
310,502
289,379
436,871
224,296
250,760
227,217
277,537
380,592
299,755
422,137
320,763
328,997
302,440
0
422,016
0
0
00422,0160302,440328,997320,763422,137299,755380,592277,537227,217250,760224,296436,871289,379310,50288,72183,17880,346275,821
   > Long-term Liabilities 
0
1,646,372
1,634,700
1,626,329
1,645,140
1,746,104
1,792,876
1,805,854
1,825,726
1,786,576
1,854,759
2,055,250
2,718,446
3,101,639
3,001,063
3,113,212
3,193,259
3,233,374
3,106,463
3,086,088
2,937,089
2,937,0893,086,0883,106,4633,233,3743,193,2593,113,2123,001,0633,101,6392,718,4462,055,2501,854,7591,786,5761,825,7261,805,8541,792,8761,746,1041,645,1401,626,3291,634,7001,646,3720
       Capital Lease Obligations 
0
302,730
294,770
276,658
264,924
262,540
269,066
259,091
261,880
265,359
257,748
251,016
244,243
238,041
241,216
495,740
491,978
487,043
475,014
464,559
454,845
454,845464,559475,014487,043491,978495,740241,216238,041244,243251,016257,748265,359261,880259,091269,066262,540264,924276,658294,770302,7300
       Long-term Liabilities Other 
0
26,373
26,666
26,572
27,195
26,845
26,935
27,449
91,965
90,933
25,912
25,453
91,637
90,990
90,564
90,627
83,117
83,342
24,070
23,711
23,437
23,43723,71124,07083,34283,11790,62790,56490,99091,63725,45325,91290,93391,96527,44926,93526,84527,19526,57226,66626,3730
> Total Stockholder Equity
3,282,800
3,434,741
3,228,332
3,247,294
3,194,567
3,309,220
3,340,770
3,294,337
3,208,701
3,207,111
2,958,246
2,775,954
2,941,689
3,054,026
2,942,580
2,909,323
2,929,005
3,064,662
3,221,884
3,536,720
3,514,485
3,514,4853,536,7203,221,8843,064,6622,929,0052,909,3232,942,5803,054,0262,941,6892,775,9542,958,2463,207,1113,208,7013,294,3373,340,7703,309,2203,194,5673,247,2943,228,3323,434,7413,282,800
   Common Stock
867,471
867,471
867,471
867,471
867,471
867,471
867,471
867,471
867,471
867,471
867,471
867,471
867,471
867,471
867,471
867,471
867,471
0
867,471
0
0
00867,4710867,471867,471867,471867,471867,471867,471867,471867,471867,471867,471867,471867,471867,471867,471867,471867,471867,471
   Retained Earnings 
2,167,709
1,916,037
1,708,664
1,739,832
2,173,931
2,291,972
2,307,826
2,302,947
2,273,885
2,279,642
2,102,095
1,925,255
2,117,818
2,141,377
1,970,389
1,780,841
1,738,375
892,507
1,453,703
972,688
1,305,381
1,305,381972,6881,453,703892,5071,738,3751,780,8411,970,3892,141,3772,117,8181,925,2552,102,0952,279,6422,273,8852,302,9472,307,8262,291,9722,173,9311,739,8321,708,6641,916,0372,167,709
   Accumulated Other Comprehensive Income 000000000000000000000
   Capital Surplus 000000000000000000000
   Treasury Stock000000000000000000000



Balance Sheet

Currency in TWD. All numbers in thousands.




Cash Flow

Currency in TWD. All numbers in thousands.




Income Statement

Currency in TWD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue4,591,894
Cost of Revenue-2,444,674
Gross Profit2,147,2202,147,220
 
Operating Income (+$)
Gross Profit2,147,220
Operating Expense-4,519,749
Operating Income72,145-2,372,529
 
Operating Expense (+$)
Research Development206,595
Selling General Administrative1,868,480
Selling And Marketing Expenses0
Operating Expense4,519,7492,075,075
 
Net Interest Income (+$)
Interest Income50,860
Interest Expense-106,097
Other Finance Cost-0
Net Interest Income-55,237
 
Pretax Income (+$)
Operating Income72,145
Net Interest Income-55,237
Other Non-Operating Income Expenses0
Income Before Tax (EBT)256,25472,145
EBIT - interestExpense = -106,097
143,943
250,040
Interest Expense106,097
Earnings Before Interest and Taxes (EBIT)0362,351
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax256,254
Tax Provision-86,967
Net Income From Continuing Ops169,287169,287
Net Income143,943
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net055,237
 

Technical Analysis of Orient Europharma Co Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Orient Europharma Co Ltd. The general trend of Orient Europharma Co Ltd is BULLISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Orient Europharma Co Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (28.6%) Bearish trend (-28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Orient Europharma Co Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 45.40 < 45.80 < 47.60.

The bearish price targets are: 39.65 > 39.10 > 37.70.

Tweet this
Orient Europharma Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Orient Europharma Co Ltd. The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Orient Europharma Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Orient Europharma Co Ltd. The current macd is -0.19224273.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Orient Europharma Co Ltd price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Orient Europharma Co Ltd. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Orient Europharma Co Ltd price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Orient Europharma Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartOrient Europharma Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Orient Europharma Co Ltd. The current adx is 41.17.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Orient Europharma Co Ltd shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Orient Europharma Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Orient Europharma Co Ltd. The current sar is 44.59.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Orient Europharma Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Orient Europharma Co Ltd. The current rsi is 38.59. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
Orient Europharma Co Ltd Daily Relative Strength Index (RSI) ChartOrient Europharma Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Orient Europharma Co Ltd. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Orient Europharma Co Ltd price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Orient Europharma Co Ltd Daily Stochastic Oscillator ChartOrient Europharma Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Orient Europharma Co Ltd. The current cci is -105.0986051.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Orient Europharma Co Ltd Daily Commodity Channel Index (CCI) ChartOrient Europharma Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Orient Europharma Co Ltd. The current cmo is -34.6951983.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Orient Europharma Co Ltd Daily Chande Momentum Oscillator (CMO) ChartOrient Europharma Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Orient Europharma Co Ltd. The current willr is -86.36363636.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Orient Europharma Co Ltd Daily Williams %R ChartOrient Europharma Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Orient Europharma Co Ltd.

Orient Europharma Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Orient Europharma Co Ltd. The current atr is 0.82661212.

Orient Europharma Co Ltd Daily Average True Range (ATR) ChartOrient Europharma Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Orient Europharma Co Ltd. The current obv is 19,897,610.

Orient Europharma Co Ltd Daily On-Balance Volume (OBV) ChartOrient Europharma Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Orient Europharma Co Ltd. The current mfi is 46.43.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Orient Europharma Co Ltd Daily Money Flow Index (MFI) ChartOrient Europharma Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Orient Europharma Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-23STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-11-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-30CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-25STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-03WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-05BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-09ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-10ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-23STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Orient Europharma Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Orient Europharma Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.594
Ma 20Greater thanMa 5042.730
Ma 50Greater thanMa 10041.578
Ma 100Greater thanMa 20040.150
OpenGreater thanClose40.600
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Orient Europharma Co Ltd with someone you think should read this too:
  • Are you bullish or bearish on Orient Europharma Co Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Orient Europharma Co Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Orient Europharma Co Ltd

I send you an email if I find something interesting about Orient Europharma Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Orient Europharma Co Ltd.

Receive notifications about Orient Europharma Co Ltd in your mailbox!